Roivant in talks to sell bowel disease drug to Roche in over $7 billion deal – WSJ

This post was originally published on this site

The sale of the drug could be announced in the coming days, the report said, citing people familiar with the matter. The talks could still fall apart and another suitor could swoop in, it added.

Shares of Roivant rose 12.8% in extended trade.

Roivant’s experimental drug, RVT-3101, is under clinical trials for the treatment of moderate-to-severe ulcerative colitis, a long-term condition where the colon and rectum become inflamed, as well as a type of inflammatory bowel disease known as Crohn’s disease.

RVT-3101 showed improvement in inflammation and ulcers in colon, when compared to placebo, in a mid-stage study in June.

Roivant declined to comment, whereas Roche did not immediately respond to a Reuters request for comment.